Pre-clinical development, Drug discovery, Pharmacology, Pharmaceutical industry, Clinical trial, Clinical research

Applied Therapeutics Takes Action Against Fraudulent “Short Report”

On Jul 6, 2020
@WillauerProsky shared
Applied Therapeutics Takes Action Against Fraudulent “Short Report” #activistshorts https://t.co/X6sLB3TQ9l
Open

On July 1, 2020, a fraudulent “short report” was posted. The fraudulent report includes manipulated company graphs and figures, fraudulent misrepresentation of data, and factual misstatements. Applied Therapeutics will work with law enforcement and regulators to ensure this criminal stock

ir.appliedtherapeutics.com
On Jul 6, 2020
@WillauerProsky shared
Applied Therapeutics Takes Action Against Fraudulent “Short Report” #activistshorts https://t.co/X6sLB3TQ9l
Open

Applied Therapeutics Takes Action Against Fraudulent “Short Report”

Applied Therapeutics Takes Action Against Fraudulent “Short Report”

On July 1, 2020, a fraudulent “short report” was posted. The fraudulent report includes manipulated company graphs and figures, fraudulent misrepresentation of data, and factual ...

CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia

CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia

ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON , April 16, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today ...

Sutro Biopharma to Present at 38th Annual J.P. Morgan Healthcare Conference

Sutro Biopharma to Present at 38th Annual J.P. Morgan Healthcare Conference

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to ...

Sutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and Controller

Sutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and Controller

SOUTH SAN FRANCISCO, Calif., May 21, 2020– Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focusedon the application of precise ...

Salarius Pharmaceuticals to Present at Biotech Showcase 2020

Salarius Pharmaceuticals to Present at Biotech Showcase 2020

HOUSTON, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused...

Innate Pharma Provides Update on Lacutamab TELLOMAK Trial

Innate Pharma Provides Update on Lacutamab TELLOMAK Trial

MARSEILLE, France, Dec 13, 2019 (GLOBE NEWSWIRE via COMTEX) -- MARSEILLE, France, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Innate Pharma SA (euronext paris:IPH -...

Data Showing Potential for Machine Learning to Advance Understanding of Nonalcoholic Steatohepatitis (NASH) Presented at the Liver Meeting® 2019

Data Showing Potential for Machine Learning to Advance Understanding of Nonalcoholic Steatohepatitis (NASH) Presented at the Liver Meeting® 2019

Data Showing Potential for Machine Learning to Advance Understanding of Nonalcoholic Steatohepatitis (NASH) Presented at the Liver Meeting® 2019

CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies

CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies

The Investor Relations website contains information about Vertex Pharmaceuticals's business for stockholders, potential investors, and financial analysts.

Athersys Announces Commencement of Patient Enrollment in the MACOVIA Study, a Pivotal Phase 2/3 Trial Evaluating MultiStem® Cell Therapy for COVID-19 Induced ARDS

Athersys Announces Commencement of Patient Enrollment in the MACOVIA Study, a Pivotal Phase 2/3 Trial Evaluating MultiStem® Cell Therapy for COVID-19 Induced ARDS

Rapid advancement of clinical program for the treatment of ARDS based on prior clinical data reflecting favorable tolerability data and meaningful benefits on mortality, ventilator-free ...

Aquestive Files IND to Begin Clinical Trials of Sublingual Epinephrine

Aquestive Files IND to Begin Clinical Trials of Sublingual Epinephrine

Epinephrine you slip under your tongue takes another step forward as the company submits their IND application.